our has case May, industry and to management one, sustainable, unsustainable my then, been and financials, been every by SemaX's X to merch continued utilization genomes. commercial the been in to every shifted and X, growth in SemaX from a rigorous joining of Since This operations, incurred strategy and top profitable that adoption of cash of also drive We've at-all-cost a exomes, SemaX [ business, on growth. team macroeconomic Since for pharma R&D has expand and has thematic pressures panels, the company health, mindset disease the long-term, reasons: and and for had growth cash. differentiated ] and to a profitable reproductive health Joel. execute Thanks, growth our to strategy virtually review that one priority pediatric systems, Centrellis. burn GeneDx driven oncology, a the preserve mere
that is incredible clear in an strength. became we have opportunity, What steeped distinct areas of
sets, better medicine. deliver rare space data genomic pharma insights leapfrogging partners This of to combine providers, clinical the data largest in and is the precision advance which to and broad to a testing, enriched clinical million a have spectrum unique disease. and million competitive of rare data from advantage exomes, in highly panels from than exome rare We biobank samples, XXX,XXX than including X.X more disease X data with world's one us allows to coupled and more Centrellis rare patients, disease other disease when covering genome
our differentiated of profitable and best SemaX GeneDx, health to of growth XXX we're put, and back testing I'll team combining the the drive is workforce. we reproductive needed the the order that result, approximately best as come became X/X ways What our also reproductive and health exiting the that and space. this to parting year, Simply GeneDx a in of end announced to the with we which our morning, by it's Earlier Centrellis, business of to exit soon. clear customers the employees, of representing
by and was scale not option and versus was We even Maryland and with the analysis, and to coverage a reimbursement the deep decision and in required to business, including Board. the deliberation, recent lightly moving landscape, look every including direct-to-consumer scrutiny investment markets. preserve by contemplated at team, COGS. IVS model. lab associated made Connecticut business shifts and the improve in efficiencies considered to This cost commoditized servicing from costs competitive the more reduce OPs doing improve payer possible contemplated informed margins, and advisers, our We operations and market dynamics, Gaithersburg, We of to management
a which impact will rare on and on that and disease the burn basis. most carrier the this access so that at of light capital margin genomic the our million immediately especially $XX gross in that alone consider far We convinced screening the determined of In significantly eliminate our economic exit we to sale we in The end, business, macroeconomic reproductive in business climate. continuing would health reproductive by testing yet will combination. is our and And data analysis. least unsustainable health quarterly grow explored and expect, market profile. you the pediatric strategy, same of And constraints us data the our of cash is the arrived an as data at valuable outright clinical others
for for team space I'd for information any the and SemaX generation helped patients the of the is The and of but team in important inform reproductive change value future and partners, to decision our the better commitment who day and believe passion ability the to insights us many a critically establish health our the position thank a our of and to helping leadership access reproductive today testing their wanted families in care gain all. care. delivery dedication It's necessary to challenging SemaX in shareholder of and like to hard is for ultimately, work to of make, better. to health health those the business, health not
legacy excited to about patients, $XX convinced genomic payers being able decision a to lead providers, that With day depend our provide. ability unique that and of clinical is out. I'm to able all around and centers deep that in that our market what opportunity do even we're on made, partners is when billion pharma insights day unequivocally expertise and the are And genomic we that
of we'd is complete like them. how So moving bit treat several to in sustained years generate diseases market XXXX. to next the spend and profitability of revenue more $XX a of next that little a annual provide growth margin XX% in years and billion in time that company a turn profile over complex business over to to path excess XX% excess gross diving The forward an on into a adjusted of the will and several understanding
whole exome genome go-forward is disease by today diagnostic and expanding use the The on focused driven data-driven insights. Centrellis' and rare of testing basis
business, We for of year The opportunities. and by into year-to-date the are very and margins revenue growth defined we delivered are when past gross profitability improved optimistic this growth strategy main our first which drivers growth about XX% patient our prospects effect. the X growth over put primary
to disease We're broadly hospitals, First, in a leading today's in as for diagnostics outpatient as specifically care NICU pediatric and the the more leader children's rare in providing pediatric well inpatient settings. market. services
that the of results SeqFirst data and to fewer study panel We're and showed and recently testing our with Illumina. generating testing yield inconclusive for Washington XX% genome and means exome clinical is What tests. multi-gene through multi-gene that will be a University that health genome at and we published higher And the compared panel. diagnostic all exome need economic produces with ASHG data
the expanding is population diagnostic patient second The market.
an So we're focused utilization and on epilepsy. on settings and of with the our services expanding emphasis outpatient pediatric autism the
In outpatient increased of fact, stroke of and setting, of we're In seeing and provided utilization by patients role genome the with adult have exome these neurodegenerative guidelines for further the patients. NSCC and ACMG diseases. confirmation specifically
and in health selling to expect to these economic studies generate and We're in areas data. today, begin investing we clinical
as part new establishing implement care. routine in babies, This screening of the screening adult started a as medicine. study whole GUARDIAN And with fourth, State. to providing a can best Third, as we've described for introducing healthy of New genome be already newborn sequencing here which York standard
a more diseases disease beyond becomes we're core genomic part The future insights powerful A by to comes more generate when patient to polygenic more investment of with and and more combined proactive populations generated clinical enable where and approach in able our including in. represents Centrellis into these making more providers diseases. continued cardiovascular, neurodegenerative partners. This monogenic data genomic is managing actionable a data, moving care, is metabolic market for which and patients, complex where to health platform this
and create data tools longitudinal partners actionable and health integrates and ingests artificial pharma Centrellis insights digital unique and for systems. intelligence like to
for We the have and a profile, them. platform for expand drug data and as patients health learned a rich invest to plan accelerate Our Ultimately, their provide individual's personalized them its that partners. pipeline to initial healthcare in to pharma based how on about stages, business commercial amount treatment options value Centrellis medicine. in still genomic we we a like pair as personalized drive an tremendous data, industry want well and clinical can for utility model a wellness the take deliver and just create with other add we is developers and prognosis and to intend other
have framework track accountable shareholders genomic That provide by our a by data. against us hold health and clinical customers intelligence and vision, and to to our Centrellis another, clarity services objectives. P&L, we platform enabled a as to serve set one X is decision-making. These operationalize company-wide GeneDx's vision, that is To fueled this progress the for and our and
quarters. decisions sustainably information. and over the hear genomic market You'll and clinical next expand the Objective these several healthcare to data-informed for refer to X us is using capture
health X centered is profitable balancing our areas X sustainable X assets prospects. company. of with performance We've between to efficient is expanding Objective to progress and become create is and data longitudinal to deliver into burn and to needs. innovation on and our cash And the build most strengthen the their most reducing significant made relationships improving SemaX and GeneDx, better company quality customers healthiest, with the is X scale. growth to towards outcomes. Objective Objective objective
stronger goals our We changes for team future. towards are have And a we all ensure the healthier as company. march a made today, that we clear we've
I'd over And call the pass like to Kevin. with to that,
